GlobalGov › Germany › Pharmaceuticals › Solicitation

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Leuprorelin, ATC L02AE02

Health · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

August 03, 2027
Response Due
Active
Status

Opportunity Overview

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Leuprorelin, ATC L02AE02 is a active solicitation for government procurement in Germany, issued by Health and tracked by GlobalGov. It falls under Pharmaceuticals. Responses are due by August 03, 2027. It was published on August 14, 2025. Full solicitation details, all dates, and related live opportunities are below.

This is one of 1,400 active Germany Pharmaceuticals opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyHealth
CountryGermany
CategoryPharmaceuticals
PublishedAugust 14, 2025
Procurement stageActive solicitation
Response dueAugust 03, 2027
StatusOpen — accepting responses
TranslationTranslated from German by GlobalGov’s translation pipeline
Official sourceView original notice
Last verifiedAugust 09, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Germany market overview →Pharmaceuticals tenders in Germany →Browse all categories →

Related Opportunities in Germany

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Timolol (ATC-Code nach WHO: S01ED01)
Germany – Pharmaceutical products – Abschluss nicht exklusiver Rabattverträge gemäß §§ 130a Abs. 8/130c Abs. 1 SGB V zu Arzneimitteln mit dem Wirkstoff Erythropoietin (B03XA01) im Rahmen eines sogenannten Open-House-Modells.
Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-06 - Pegvisomant
Germany – Pharmaceutical products – Abschluss nicht exklusiver Rabattverträge gemäß §§ 130a Abs. 8/130c Abs. 1 SGB V zu Arzneimitteln mit dem Wirkstoff Sultiam (N03AX03), nur Filmtabletten im Rahmen eines sogenannten Open-House-Modells.
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Denosumab, Handelsname Prolia, ATC M05BX04
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Hausstaubmilben, ATC V01AA03
Germany – Pharmaceutical products – Open-House Arzneimittelrabattverträge gemäß § 130a Abs. 8c SGB V Trastuzumab, ATC L01FD01 - Vertragsregionen Niedersachsen, Bremen und Sachsen-Anhalt
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Flecainid (ATC-Code: C01BC04).

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.